Use of Exemestane and Product containing Exemestane

摘要

Use of aromatase inhibitor, exemestane, either alone or in combination with other therapeutic agents in cancer chemoprevention of estrogen dependent in Mammals, including humans, high risk.Product containing Exemestane and other Therapeutic Agent selected from a compound nonsteroidal anti-inflammatory Drug (NSAID), a retinoid Compound, an inhibitor of farnesyl Protein transferase inhibitor of matrix metalloprotease Inhibitor, Integrin avb3; inhibitor The protein kinase, linomida, angiostatin, dehydroepiandrosterone (DHEA),A telomerase Inhibitor, Platelet factor 4 (endostatin, arzoxifene, indoxifeno), a cyclooxygenase Inhibitor, its 5416, 6668, razoxin, fluvestrant 800 ms, and thalidomide, or a mixture thereof, as a combined preparation for simultaneous, separate or Sequential use in t, Treatment of estrogen dependent cancer.Product containing Exemestane and other chemopreventive Agent selected from a compound of Taxane Compound, a nonsteroidal anti-inflammatory Drug (NSAID), a retinoid Compound, an inhibitor of farnesyl Protein transferase inhibitor of matrix metalloprotease Inhibitor, r Ntegrina avb3, consisting of an anthracycline, a monoclonal antibody against HER2.Or antagonist and inhibitor of EGFR, a protein kinase inhibitor, linomida, angiostatin, a cyclooxygenase Inhibitor, razoxin, dehydroepiandrosterone (DHEA), a telomerase Inhibitor, Platelet factor 4 (endostatin), an antiestrogen, an inhibitor of VEGF and thalidomide, or a mixture The Same, as a combined preparation for Concurrent use.Separately or successively in chemoprevention and control the growth of estrogen dependent cancer.